Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis

Executive Summary

• Thiogenesis Therapeutics announced plans to launch a pivotal Phase 3 trial of its lead candidate TTI‑0102 for nephropathic cystinosis, with an IND filing expected in early 2026.
• The trial will use the FDA’s 505(b)(2) pathway and leverages dosing and biomarker data from the company’s ongoing Phase 2 MELAS study to support once‑daily oral administration.
• Successful execution positions TTI‑0102 as a next‑generation cysteamine prodrug that could capture a $300 million global market for cystinosis therapy.

Key Details

• Indication: Nephropathic cystinosis – rare lysosomal storage disorder affecting >2,000 patients worldwide.
• Candidate: TTI‑0102, a sulfur‑based disulfide prodrug delivering sustained cysteamine exposure with reduced peak‑related GI toxicity.
• Trial Design: Pivotal Phase 3 study under FDA 505(b)(2) regulatory pathway; endpoints and design informed by biomarker and tolerability data from the Phase 2 MELAS program.
• Dosing Strategy: Intended once‑daily oral dosing, derived from exposure‑response and weight‑based tolerability insights obtained in MELAS.
• Regulatory Timeline: IND submission targeted for early 2026; trial initiation planned shortly thereafter.
• Market Opportunity: Global cystinosis market estimated >$300 million; current standard of care (Cystagon®, Procysbi®) requires twice‑daily dosing with notable side effects.
• Competitive Advantage: Potential for reduced dosing frequency, improved tolerability, and dual mechanism (cystine depletion + antioxidant pathway enhancement).
• Leadership Quote: “TTI‑0102 was engineered specifically to overcome the limitations of existing cysteamine formulations… we believe it represents the next‑generation therapy that would significantly increase patients’ quality of life.” – Dr. Patrice Rioux, CEO.

Notable Quotes

“We understand the underlying mechanism of cystinosis at a deep biochemical level… By enabling the potential for once‑daily or reduced dosing with a far better tolerability profile, we believe TTI‑0102 represents the next‑generation therapy that patients and families would significantly increase their quality of life.” – Dr. Patrice Rioux, Chief Executive Officer.